国际肿瘤学杂志

国际肿瘤学杂志››2012,Vol. 39››Issue (10): 755-758.

• 综述 •上一篇下一篇

树突状细胞与肿瘤免疫治疗

李文翔,牛伟新

  1. 200032 上海，复旦大学中山医院普外科
  • 出版日期:2012-10-31发布日期:2012-10-31
  • 通讯作者:牛伟新，E-mail:niu.weixin@zs-hospital.sh.cn E-mail:niu.weixin@zs-hospital.sh.cn

Dendritic cells and tumor immunotherapy

LI Wen-Xiang, NIU Wei-Xin

  1. Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032， China
  • Online:2012-10-31Published:2012-10-31
  • Contact:NIU Wei-xin， E-mail:niu.weixin@zs-hospital.sh.cn E-mail:niu.weixin@zs-hospital.sh.cn

PDF

1877

摘要：树突状细胞（DC）是体内功能最强大的抗原提呈细胞（APC），以DC为基础的肿瘤免疫治疗成为近来的研究重点。DC不仅可以作为细胞疫苗单独介导抗肿瘤免疫，而且还可以与细胞因子、免疫细胞以及其他的方法联合用于肿瘤的免疫治疗。动物模型和临床试验中，以DC为基础的免疫治疗以及其他的肿瘤免疫治疗策略都取得了较为显著的进展。

关键词:树突细胞,肿瘤,免疫

Abstract:In vivo, dendritic cells（DCs）are the most powerful antigenpresenting cells （APCs）. DCs based neoplasm immunotherapy has recently become the focus of research. DCs can be used not only as separate cell vaccine to mediate antitumor immunity, but can also be combined with cytokines, immune cells, and other methods in tumor immunotherapy. In animal models and clinical trials, DCbased immunotherapy as well as other tumor immunotherapy strategies have gained more significant progress.

Key words:Dendritic cells,Neoplasms,Immunity